Explore

Trendline Trendline
Eli Lilly to Acquire CrossBridge Bio to Enhance Antibody-Drug Conjugate Development

Eli Lilly to Acquire CrossBridge Bio to Enhance Antibody-Drug Conjugate Development

Eli Lilly to Acquire CrossBridge Bio to Enhance Antibody-Drug Conjugate Development
Trendline Trendline
Parabilis Medicines Expands Leadership Team to Drive Cancer Drug Development

Parabilis Medicines Expands Leadership Team to Drive Cancer Drug Development

Parabilis Medicines Expands Leadership Team to Drive Cancer Drug Development
Trendline Trendline
Ardena Expands Bioanalytical Capabilities with New Laboratory in New Jersey

Ardena Expands Bioanalytical Capabilities with New Laboratory in New Jersey

Ardena Expands Bioanalytical Capabilities with New Laboratory in New Jersey
Trendline Trendline
Iterion Therapeutics Presents New Data on Tegavivint for Wnt-Driven Cancers at AACR Meeting

Iterion Therapeutics Presents New Data on Tegavivint for Wnt-Driven Cancers at AACR Meeting

Iterion Therapeutics Presents New Data on Tegavivint for Wnt-Driven Cancers at AACR Meeting
Trendline Trendline
Parabilis Medicines Strengthens Leadership with Key Appointments to Drive Growth

Parabilis Medicines Strengthens Leadership with Key Appointments to Drive Growth

Parabilis Medicines Strengthens Leadership with Key Appointments to Drive Growth
Trendline Trendline
Kivu Bioscience Names Mohit Trikha as New CEO to Lead ADC Development

Kivu Bioscience Names Mohit Trikha as New CEO to Lead ADC Development

Kivu Bioscience Names Mohit Trikha as New CEO to Lead ADC Development
Trendline Trendline
Frontier Medicines Appoints David R. Epstein to Board to Drive Drug Development

Frontier Medicines Appoints David R. Epstein to Board to Drive Drug Development

Frontier Medicines Appoints David R. Epstein to Board to Drive Drug Development
Trendline Trendline
Frontier Medicines Appoints David R. Epstein to Board Amid Precision Medicine Expansion

Frontier Medicines Appoints David R. Epstein to Board Amid Precision Medicine Expansion

Frontier Medicines Appoints David R. Epstein to Board Amid Precision Medicine Expansion
Trendline Trendline
Frontier Medicines Appoints David R. Epstein to Board of Directors to Drive Growth

Frontier Medicines Appoints David R. Epstein to Board of Directors to Drive Growth

Frontier Medicines Appoints David R. Epstein to Board of Directors to Drive Growth
Trendline Trendline
IDEAYA and Servier's Eye Cancer Drug Advances to FDA with Promising Efficacy

IDEAYA and Servier's Eye Cancer Drug Advances to FDA with Promising Efficacy

IDEAYA and Servier's Eye Cancer Drug Advances to FDA with Promising Efficacy
Trendline Trendline
Vir Biotechnology Begins Phase 1 Expansion for Prostate Cancer Treatment

Vir Biotechnology Begins Phase 1 Expansion for Prostate Cancer Treatment

Vir Biotechnology Begins Phase 1 Expansion for Prostate Cancer Treatment
Trendline Trendline
San Diego Startup Neomorph Secures $100 Million Investment for Cancer Drug Development

San Diego Startup Neomorph Secures $100 Million Investment for Cancer Drug Development

San Diego Startup Neomorph Secures $100 Million Investment for Cancer Drug Development